These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17512448)

  • 21. Salvage chemotherapy of breast cancer.
    Norton L
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):19-24. PubMed ID: 8091238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
    Köstler WJ; Brodowicz T; Zielinski CC;
    J Natl Cancer Inst; 2010 Feb; 102(3):207; author reply 207-8. PubMed ID: 20054016
    [No Abstract]   [Full Text] [Related]  

  • 23. Preference weights for chemotherapy side effects from the perspective of women with breast cancer.
    Kuchuk I; Bouganim N; Beusterien K; Grinspan J; Vandermeer L; Gertler S; Dent SF; Song X; Segal R; Mazzarello S; Crawley F; Dranitsaris G; Clemons M
    Breast Cancer Res Treat; 2013 Nov; 142(1):101-7. PubMed ID: 24129976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of primary prophylactic granulocyte-colony stimulating factor use on incidence of neutropenia hospitalizations for elderly early-stage breast cancer patients receiving chemotherapy.
    Rajan SS; Lyman GH; Stearns SC; Carpenter WR
    Med Care; 2011 Jul; 49(7):649-57. PubMed ID: 21478779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
    Mackey JR; Ramos-Vazquez M; Lipatov O; McCarthy N; Krasnozhon D; Semiglazov V; Manikhas A; Gelmon KA; Konecny GE; Webster M; Hegg R; Verma S; Gorbunova V; Abi Gerges D; Thireau F; Fung H; Simms L; Buyse M; Ibrahim A; Martin M
    J Clin Oncol; 2015 Jan; 33(2):141-8. PubMed ID: 25185099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
    Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
    Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life as a treatment endpoint in metastatic breast cancer.
    Osoba D
    Can J Oncol; 1995 Dec; 5 Suppl 1():47-53. PubMed ID: 8853525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer.
    Awada A
    Forum (Genova); 2002; 12(1):4-15. PubMed ID: 12634907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New agents in chemotherapy and new methods of their administration in the treatment of metastatic cancer of the breast].
    Cappelaere P
    Bull Cancer; 1989; 76(1):93-7. PubMed ID: 2713519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discouraging news for high-dose chemotherapy in high-risk breast cancer.
    Pusztai L; Hortobagyi GN
    Lancet; 1998 Aug; 352(9127):501-2. PubMed ID: 9716049
    [No Abstract]   [Full Text] [Related]  

  • 32. Approved agents for metastatic breast cancer.
    Fornier MN
    Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer.
    Grenon NN
    Clin J Oncol Nurs; 2013 Aug; 17(4):425-33. PubMed ID: 23899982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
    Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic treatment for stage I and stage II breast cancer.
    Hudis CA; Borgen P
    Surg Oncol Clin N Am; 1997 Oct; 6(4):683-98. PubMed ID: 9309088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
    Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
    Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
    Boehnke Michaud L
    J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab for advanced breast cancer.
    Goldfarb SB; Traina TA; Dickler MN
    Womens Health (Lond); 2010 Jan; 6(1):17-25. PubMed ID: 20001867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone and cyclophosphamide in advanced breast cancer: a pilot study.
    McDonald DB; Abu-Zahra H; Yoshida S; Binder H
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):19-22. PubMed ID: 6385260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in stage II breast cancer: an instrument for clinical trials.
    Levine MN; Guyatt GH; Gent M; De Pauw S; Goodyear MD; Hryniuk WM; Arnold A; Findlay B; Skillings JR; Bramwell VH
    J Clin Oncol; 1988 Dec; 6(12):1798-810. PubMed ID: 3058874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.